BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 20.09.2006

Draft Guidance for Industry on Public Availability of Labeling Changes in “Changes Being Effected” Supplements; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Public Availability of Labeling Changes in `Changes Being Effected' Supplements." The guidance announces to holders of a new drug application (NDA), an abbreviated new drug application (ANDA), or a biologics license application (BLA), who intend to submit a "Changes Being Effected" supplement (CBE supplement) to make a postapproval labeling change, that FDA will make labeling revisions identified in a CBE supplement publicly available upon receipt of the supplement by FDA. The guidance does not have any bearing on supplements that relate to chemistry, manufacturing, and controls changes, nor does it expand the circumstances in which an ANDA holder may effect labeling changes via a CBE supplement.

Source: Federal Register — Food and Drug AdministrationOpen original release →